Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells

Free Radical Biology and Medicine

Volumn 37, Issue 7, 2004, Pages 953-960

  Núñez, Marco T ^a,b   Gallardo, Viviana ^a   Muñoz, Patricia ^b   Tapia, Victoria ^b   Esparza, Andrés ^b   Salazar, Julio ^a   Speisky, Hernán ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Iniciativa Cientifica Milenio Santiago   (Chile)

Author keywords

Free radicals; Oxidative stress; Parkinson's Disease; Redox potential; SH SY5Y cells; Viability

Indexed keywords

GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; IRON;

ARTICLE; CELL LEVEL; CELL MEMBRANE POTENTIAL; CELL METABOLISM; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; EVALUATION; EXPOSURE; GLUTATHIONE METABOLISM; HOMEOSTASIS; HUMAN; HUMAN CELL; MOLECULAR MODEL; NEUROBLASTOMA CELL; OBSERVATION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SUBSTANTIA NIGRA;

BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; GLUTATHIONE; HUMANS; IRON; NEUROBLASTOMA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 4444301224     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.06.005     Document Type: Article

References (50)

1. Cooper A.J.L. Glutathione in the brain: disorders of glutathione metabolism. Rosenberg R.N., Prusiner S.B., DiMauro S., Barchi R.L., Kunk L.M. The molecular and genetic basis of neurological disease. 1997;1195-1230 Butterworth-Heinemann, Boston
2. Clarke D.D., Sokoloff L. Circulation and energy metabolism of the brain. Siegel G.J., Agranoff B.W., Albers R.W., Fisher S.K., Uhler M.D. Basic neurochemistry: molecular, cellular and medical aspects. 1999;637-669 Lippincott-Raven, Philadelphia
3. Meister A. Selective modification of glutathione metabolism. Science. 220:1983;472-477
4. Drukarch B., Schepens E., Jongenelen C.A., Stoof J.C., Langeveld C.H. Astrocyte mediated enhancement of neuronal survival is abolished by glutathione deficiency. Brain Res. 770:1997;123-130
5. Wang X.F., Cynader M.S. Astrocytes provide cysteine to neurons by releasing glutathione. J. Neurochem. 74:2000;1434-1442
6. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30:2001;191-212
7. Salinas A.E., Wong M.G. Glutathione S-transferases - a review. Curr. Med. Chem. 6:1999;279-309
8. ·-. Free Radic. Biol. Med. 34:2003;1078-1088
9. Sayre L.M., Perry G., Atwood C.S., Smith M.A. The role of metals in neurodegenerative diseases. Cell. Mol. Biol. 46:2000;731-741
10. Adams J.D. Jr., Klaidman L.K., Odunze I.N., Shen H.C., Miller C.A. Brain levels of glutathione, glutathione disulfide, and vitamin E. S. Mol. Chem. Neuropathol. 14:1991;213-226
11. Cardoso S.M., Oliveira C.R. Glutathione cycle impairment mediates A beta-induced cell toxicity. Free Radic. Res. 37:2003;241-250
12. Omar R.A., Chyan Y.J., Andorn A.C., Poeggeler B., Robakis N.K., Pappolla M.A. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J. Alzheimer's Dis. 1:1999;39-145
13. Double K.L., Gerlach M., Youdim M.B., Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural Transm. Suppl. 60:2000;37-58
14. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310
15. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:1986;269-274
16. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H., et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:1994;38-44
17. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130
18. Youdim M.B., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. 126:1989;47-54
19. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520
20. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807
21. Symons M.C.R., Gutteridge J.M.C. Free radicals and iron: chemistry, biology and medicine. 1998;Oxford Univ. Press, New York
22. Sayre L.M., Perry G., Harris P.L.R., Liu Y., Schubert K.A., Smith M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 74:2000;270-279
23. Perry G., Taddeo M.A., Petersen R.B., Castellani R.J., Harris P.L.R., Siedlak S.L., Cash A.D., Liu Q., Nunomura A., Atwood C.S., Smith M.A. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals. 16:2003;70-81
24. Gutteridge J.M., Halliwell B. Free radicals and antioxidants in the year 2000: a historical look to the future. Ann. N. Y. Acad. Sci. 899:2000;136-147
25. Hauptmann N., Cadenas E. The oxygen paradox: biochemistry of active oxygen. Scandalios J.G. Oxidative stress and the molecular biology of antioxidant defenses. 1997;Cold Spring Harbor Laboratory Press, New York
26. Youdim M.B., Riederer P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J. Neural Transm. Suppl. 40:1993;57-67
27. Shoham S., Youdim M.B. The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin. J. Neural Transm. 109:2002;1241-1256
28. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci. 3:2002;1-11
29. Gotz M.E., Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012:2004;193-208
30. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56:1991;446-451
31. Perry G., Raina A.K., Nunomura A., Wataya T., Sayre L.M., Smith M.A. How important is oxidative damage? Lessons from Alzheimer's disease. Free Radic. Biol. Med. 28:2000;831-834
32. Takeda A., Smith M.A., Avila J., Nunomura A., Siedlak S.L., Zhu X., Perry G., Sayre L.M. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem. 75:2000;1234-1241
33. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T., Hayakawa T., Nunomura A., Chiba S., Perry G., Smith M.A., Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273:2000;5-9
34. Connor J.R., Milward E.A., Moalem S., Sampietro M., Boyer P., Percy M.E., Vergani A., Chorney M. Is hemochromatosis a risk factor for Alzheimer disease? J. Alzheimer's Dis. 3:2001;471-477
35. Tapia V., Arredondo M., Núñez M.T. Regulation of iron absorption by cultures of epithelia (Caco-2) cells monolayers with varied iron status. Am. J. Physiol. 271:1996;G443-G447
36. Núñez-Millacura C., Tapia V., Muñoz P., Maccioni R.B., Núñez M.T. An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J. Neurochem. 82:2002;240-248
37. Zecca L., Gallorini M., Schünemann V., Alfred X., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76:2001;1766-1773
38. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1986;55-63
39. Reynolds I.J., Hastings T. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci. 15:1995;3318-3327
40. Griffith O.W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106:1980;207-212
41. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113:1985;548-555
42. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:1967;158-169
43. Veal E.A., Toone W.M., Jones N., Morgan B.A. Distinct roles for glutathione S-transferases in the oxidative stress response in Schizosaccharomyces pombe. J. Biol. Chem. 277:2002;35523-35531
44. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836
45. Forman H.J., Dickinson D.A., Iles K.E. HNE-signaling pathways leading to its elimination. Mol. Aspects Med. 24:2003;189-194
46. Krzywanski D.M., Dickinson D.A., Iles K.E., Wigley A.F., Franklin C.C., Liu R.M., Kavanagh T.J., Forman H.J. Variable regulation of glutamate cysteine ligase subunit proteins affects glutathione biosynthesis in response to oxidative stress. Arch. Biochem. Biophys. 423:2004;116-125
47. Lan J., Jiang D.H. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104:1997;649-660
48. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355
49. Mandel S., Grunblatt E., Maor G., Youdim M.B. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 27:2002;1231-1243
50. He Y., Thong P.S., Lee T., Leong S.K., Mao B.Y., Dong F., Watt F. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic. Biol. Med. 35:2003;540-547